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ABSTRACT 
 
Despite recent consensus on eligibility of adjuvant systemic therapy in lymph-node negative breast 
cancer (NNBC) patients based on clinico-pathological criteria, specific biological markers are needed to 
predict sensitivity to the different therapeutic options. We examined the feasibility of developing a 
genomic predictor of chemotherapy response and recurrence risk in 185 patients with NNBC using 
assembled arrays containing 2,460 BAC clones for scanning the genome for DNA copy number 
changes. After surgery, 90 patients received anthracycline-based chemotherapy whereas ninety-five 
did not. Tamoxifen was administered to patients with hormone-receptor positive tumors. Association of 
genomic and clinico-pathological data and outcome was computed using Cox proportional hazard 
models and multiple testing adjustment procedures. Analysis of NNBC genomes revealed a common 
genomic signature. Specific DNA copy number aberrations were associated with hormonal receptor 
status, but not with other clinico-pathological parameters. In patients treated with chemotherapy, none 
of the genomic changes was significantly correlated with recurrence. In patients not receiving 
chemotherapy, deletion of eight BAC clones clustered to chromosome 11q was independently 
associated with relapse (DFS at 10 years±SE, 40±14% vs. 86±6%;p<00001). Patients with 11q 
deletion did not show more aggressive clinical-pathological features than those without 11q loss. The 
adverse influence of 11q deletion in clinical outcome was confirmed in an independent validation series 
of 88 NNBC patients. Our data suggest that NNBC patients with 11q deletion may benefit from 
anthracycline-based chemotherapy despite other clinical, pathological or genetic features. However, 
these initial findings should be evaluated in randomized clinical trials.  
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INTRODUCTION 
 
The use of adjuvant systemic chemotherapy and/or endocrine therapy in the treatment of lymph-node 
negative breast cancer (NNBC) has increased greatly in the last decade.(1-5) Despite recent 
consensus, the group of patients with NNBC that will obtain clinical benefit from the use of adjuvant 
chemotherapy is still a problematic debate. In patient with young age, with large sized or high 
pathological grade tumors, or with hormone receptor–negative tumors, systemic chemotherapy 
improves the odds of disease-free and overall survival.(1, 2, 5, 6) Among the different chemotherapy 
regimens, those containing anthracyclines are on average more effective.(5, 6) Therapy with 
trastuzumab seems to be effective in the subset of HER2 positive NNBC.(7) However, despite obvious 
therapeutic advances, approximately one fourth of NNBC patients will have tumor recurrence that is 
potentially treatable but ultimately fatal. These data highlight the need for more sensitive and specific 
therapy-predictive indicators to refine the use of the multiple treatment options.  
 
Using gene expression profiling, several investigators have reported gene-expression signatures of 
breast tumor cells that were more powerful predictors of disease outcome than standard clinical and 
histological criteria.(8-12) However, the apparent variability and lack of reproducibility observed among 
these previous transcriptional analyses and the requirements for high-quality RNA obtained from fresh 
tissues have limited their application to the clinical setting. A different type of microarray technology, 
termed comparative genomic hybridization (CGH) to microarrays (array CGH), allows a quantitative 
detection of DNA copy number changes in tumor genomes with high resolution.(13, 14) This method 
enables the identification of precise areas in which genetic changes occur, including loss of genomic 
material (deletion) and genomic gain (amplification). These genomic alterations usually result in 
damage of specific genes involved in cancer development and progression.  In breast cancer, definition 
of recurrent genomic aberrations has revealed loci encoding genes involved in the pathogenesis of the 
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disease,(15-18) some of which have been correlated with the different pathological subtypes.(19) As 
the most prominent example, amplification of chromosome 17q12 targets HER2 gene, which results 
deregulated at the RNA and protein levels.(20) Recently, array CGH has also proven its value for 
predicting clinical outcome in prostate carcinoma, lymphoma, gastric carcinoma and acute myeloid 
leukemia.(21-23) However, to date, no similar studies have been attempted in breast cancer.  
 
In the present study, we examined the feasibility of developing a predictor of recurrence risk and 
therapeutic response for 185 NNBC patients using array CGH for scanning the entire genome for DNA 
copy number changes.  
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METHODS 
 
STUDY DESIGN AND SELECTION OF PATIENTS 
From September 1979 to June 2000, over 3.100 new breast cancer patients were diagnosed at the 
University of Valencia. Of them, 1.482 tumors were criopreserved at -80ºC. For this study, biopsies 
were randomly selected based on the following criteria for inclusion: (1) diagnosis of primary invasive 
breast carcinoma of any size; 2) treatment by modified radical mastectomy or breast-conserving 
surgery, including dissection of axillary lymph nodes, followed by radiotherapy if indicated; 3) the apical 
axillary lymph nodes were tumor-negative (pathological examination, pN0); and 4) complete clinical 
data were available. Over 363 samples fulfilled the criteria. Previous to DNA extraction, these frozen 
tumor sections were stained by hematoxylin/eosin (H&E) and reviewed for tumor infiltratrion: only those 
with clear >50% of tumoral cells were selected. A cohort of 185 patients fulfilled these final criteria. 
Clinico-pathological variables including tumor size, histological grade and subtype and ER and PR 
status were determined following standard methods as reported.(24) Human investigations were 
performed after approval by an institutional review board on scientific and ethical affairs. 
 
MICROARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ARRAY CGH)  
DNA extraction, hybridization and imaging. Frozen tumors were included in OCT compound. 
Previous to DNA extraction, H&E stained tumor sections were examined to select samples with more 
than 50% of tumoral cells. Around 20-30 sections of 25µm were used for DNA extraction. After 
removing the OCT with PBS washes, DNA was extracted as previously described.(24) Genome-wide 
analysis of DNA-copy number changes was performed using array CGH on a microchip with ∼2.460 
BAC and P1 clones printed in triplicate (UCSF Hum Array 2.0) with a resolution of 1.4 Mb across the 
genome.(25) Methods and analytical procedures have been described elsewhere in detail.(23, 25) 
Briefly, 0.5 µg of test (tumor) and reference genomic DNAs were labeled by random priming using Cy3 
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and Cy5, respectively. After 48 hour of hybridization, slides were washed and mounted with DAPI. The 
images of the arrays were captured using a CCD camera, and the “UCSF SPOT” 2.0 software 
(available at http://www.jainlab.org/downloads.html) was used to analyze the images and measure 
tumoral vs. control fluorescence intensity ratios that were converted to the log2 scale. A second 
program, the “UCSF SPROC” was used to associate clones with each spot and to create a mapping 
information file that allows the data to be plotted relative to the position of the BACs on the draft human 
genome sequence (http://genome.cse.ucsc.edu; May 2004 freeze). A formal data filtering procedure 
was then performed, and a SPROC output file consisting of averaged ratios of the triplicate spots for 
each clone, standard deviations of the replicates and plotting positions for each clone on the array, was 
obtained (Figure 1). For visualization of genomic data, the TreeView program 1.60 (Stanford, CA) was 
used. To confirm array CGH data, CGH to chromosomes was performed in 44 biopsies included in the 
study.  
Interphase FISH analysis. To confirm specific gains and losses of BAC clones observed in the array 
CGH analyses, fluorescence in situ hybridization (FISH) studies using individual BAC clones as probes 
on isolated nuclei from frozen tumor sections was performed using a reported technique.(26) The gene 
loci examined corresponded to 5 overrepresented and 4 deleted BAC clones, using appropriate 
centromeric probes as controls. A total of 100 cells were examined on each of the 22 tumors examined. 
These clones were obtained from RZPD German Resource Center (Berlin, Germany) or purchased 
from Vysis (Downers Grove, IL, US).  
 
 
STATISTICAL ANALYSIS 
Array preprocessing. In order to process the genomic data obtained with array CGH and to compare 
the genomic alterations with different clinical phenotypes we used a previously described analytical 
model.(27) Clones with ratios missing in 2 or more replicate spots (out of 3) were excluded from further 
analysis, as well as when the standard deviation of the replicates log2 ratios was above 0.2. In 
addition, clones that were successfully mapped to May 2004 release of human genome sequence and 
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were declared present in more than 75% of the samples were included in the final analysis. Duplicate 
clones were averaged. The final dataset contained 2117 unique BACs, and clone values were missing 
in a median of 5.4% of the samples. Arrays were normalized by subtracting the median of each array 
from the average log2 ratio for every clone. 
Copy number changes identification. The array CGH data were analyzed using Hidden Markov 
Model (HMM) as implemented in the Bioconductor package aCGH using the default tunning 
parameters.(27) Log2 ratios as ordered in the genome were segmented into regions of constant copy 
number. In addition, the HMM model was employed to impute missing values by using the estimated 
copy number ratio for the segment containing the clone(s) with missing values. Clones with missing 
values located between segmented regions were assigned the mean value of the segment that is 
closer in genomic distance. Thus, each clone was assigned a segment value referred to as its 
"smoothed" value. Median absolute deviation (MAD) of the difference between the observed and 
smoothed values was used to estimate the tumor-specific experimental variation. All of the tumors had 
MAD less than 0.22. Clones for each array were assigned into three groups: gained - the smoothed 
log2 ratio of a clone in a particular tumor was higher than 3 times the MAD; lost - when the smoothed 
log2 ratio was less than 3 times the -MAD; and finally, not changed - when the log2 ratio can not be 
assigned to the lost or gained groups. 
Association of copy number with phenotypes. Smoothed, imputed data was used to study 
association with the following phenotypes: age, tumor size, histological grade and subtype, stage, 
estrogen and progesterone receptor status, and recurrence/survival. For example, for the right 
censored data we used Cox proportional hazards model, where we tested for difference in survival 
given different baseline log2 ratio for a given clone. We corrected for multiple hypotheses testing by 
controlling the False Discovery Rate. Significance was claimed at the FDR < 0.05, which corresponds 
to the expectation of at most 5% of false discoveries among the loci declared significant. In addition, we 
 8 
tested for difference in recurrence/survival outcome for patients subgroups defined by the treatment 
assigned to them.  
Cross-tabulation of clinical variables. We used Fisher’s two-sided exact test 2x2 crosstabs to 
compare genomic events or clinical variables among both groups of treatment. To evaluate differences 
in disease-free survival, Kaplan-Maier survival curves for the sets of patients were examined. 
GO validation. Finally, we performed a statistical analysis to check if there were any gene Ontology 
(GO) categories that were enriched in the genes located in the region of deletion in chromosome 
11q23-q24 with respect to the whole genome 
 
CLINICAL SERIES FOR VALIDATION OF ARRAY CGH RESULTS 
To validate the possible association of chromosome 11q deletion with increased relapse rate, this was 
tested in a validation group of 88 tumor biopsy samples from an independent cohort of NNBC patients. 
These were 18 Spanish patients treated in different Institutions within the Valencia area whose 
genomes were analyzed with array CGH as described above. In addition, data from 70 patients were 
obtained from a recently published series of American breast cancer patients analyzed using similar 
whole-genome array CGH techniques (Chin et al, submitted). All patients fulfilled the reported inclusion 
criteria of the study. Kaplan-Maier survival curves for the two sets of patients were evaluated. Clinico-
pathological characteristics of the validation series are shown in Supplemental Table S1. 
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RESULTS 
 
CHARACTERISTICS OF THE PATIENTS 
Clinico-pathological characteristics of the 185 patients and tumors are summarized in Table 1. Based 
on the clinico-pathological features, 90 women received anthracycline-based chemotherapy (CHEMO 
group) whereas 95 patients did not (non-CHEMO group). In both groups, women with ER/PR positive 
tumors were treated with tamoxifen: 42 in the CHEMO group (47%) and 56 in the non-CHEMO group 
(59%) (Supplemental Table S2). With a median duration of follow-up time of 82 months (range, 9 to 
218 months), 45 of the 185 patients (24%) have relapsed. Median duration of follow-up time for 
patients who are free of disease was 96 months in both CHEMO and non-CHEMO groups. Death from 
the disease was assessed in 16 of 185 patients (9%). We initially determined differences in clinico-
pathological features and outcome between patients in the CHEMO group vs. those in the non-CHEMO 
group. Women in CHEMO group were younger (mean, 51 vs. 67 years; p=0,003) and had a more 
frequent pre-menopausal status (43 vs. 17%; p=0,001). We did not observe statistically significant 
differences in any other histopathological feature (Table 1 and Supplemental Fifure S1A). In addition, 
no statistically significant differences in disease-free survival (DFS) and overall survival (OS) were 
found between CHEMO and non-CHEMO groups (Supplemental Fifure S1B and S1C). 
 
GENOMIC PROFILING OF LYMPH-NODE NEGATIVE BREAST CANCER 
Array CGH analysis was performed in the 185 tumor biopsies, and allowed the identification of specific 
regions of gain and loss throughout the genome with high resolution in all of the biopsies. All tumors 
showed genomic changes (Figure 2). A total of 112 clones that were mapped to 40 different 
chromosome loci in 9 different chromosome arms were found. These corresponded to 23 genomic 
gains and 17 genomic losses involving regions known to be commonly involved in breast cancer as 
well as uncharacterized genomic aberrations. The most common gains corresponded to chromosomes 
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1q31 and 20q12 (91 of 185, 49%), 8q24.2 (40%), 17q21 (39%), 1q32, 8q23.1 and 20q13.1 (35%), 1q23 
(34%) and 8q24.1 at MYC gene locus (32%). In addition, high-level amplification (defined as log2 ratio 
>1 observed in at least 10 different samples) was identified in 5 different regions of chromosomes 
11q13-q14 at CCND1 gene (17 of 185 tumors, 9%), HER2 (13 tumors, 7%), 1q31 and 8p12 at FGFR1 
gene (11 tumors, 6%) and 8q21-q24.1 including MYC gene (10 tumors, 5%). The most frequently 
deleted regions were observed at chromosomes 13q14-q22 (66 of 185 tumors, 36%), 17p12-p13 
including P53 gene locus (34%), 16q21-q22 including the CDH1 gene (30%), and 11q21-q25 (29%), 
16q24 and 16p12-p13.1 (26%), 11q12 (25%), 8p21.3-p22 (25%) and 22q11.2. A total of 18 
homozygous deletions (defined as log2 ratio below -1,4) were identified, being the loss of 13q21.3-q22 
at KLF12 gene observed in two different tumors. The full array CGH data has been deposited in GEO 
database (Platform GPL3632). 
 
To initially validate the array CGH results, a subset of 44 samples was also analyzed with CGH to 
chromosomes, and the two techniques showed concordant values (Supplemental Figure S2). To 
further validate our data, the analysis of 9 individual BAC clones in 22 frozen tumor sections using 
fluorescence in situ hybridization (FISH) also showed a high concordance with array CGH results 
(Supplemental Table S3).  The array CGH data defined a common genomic signature of NNBC (Figure 
2; detailed information in Supplemental Table S4).  
 
CORRELATION OF GENOMIC ALTERATIONS AND CLINICOPATHOLOGICAL FEATURES 
We tested the association of clinical and pathological variables with each of the BAC clones in the 185 
patients. After adjustment for multiple testing, these analyses showed that the only variables correlated 
with genomic changes were ER and PR status (Figure 3). Tumors that showed expression of ER (ER+) 
presented with frequent gain of chromosomes 1q21-q43 (35% vs. 14%; p<0,05), and 16p12 (17% vs. 
1%; p<0,01) and losses of chromosome 16q21-q24 (25% vs. 7%; p<0,01). Tumors negative for PR 
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(PR-) also presented with frequent deletion of chromosomes 4p13-p16 (19 vs. 5%; p<0,001) and 
5q11.2-q31 (16 vs. 3%; p<0,001) (Figure 3B and Supplemental Table S5). We also determined the 
correlation of the genomic status of 17q12 locus at HER2 gene (determined by array CGH analysis) 
with other clinical variables. Amplification or gain of HER2 gene was observed in 29 tumors (16%) and 
was correlated with negativity for PR expression (p=0,007), but not with other clinico-pathological 
features. 
 
ASSOCIATION OF GENOMIC ABNORMALITIES WITH CLINICAL OUTCOME: 11q LOSS 
PREDICTS RESPONSE TO CHEMOTHERAPY 
We compared the genomic profiles of tumors in the CHEMO and non-CHEMO groups. None of the 
abnormal BAC clones showed a significantly different distribution between the two cohorts, indicating 
that both groups were comparable at the genomic level (Figure 2).  To develop a genomic predictor of 
clinical outcome, we examined the association of the genomic aberrations with disease recurrence in 
the two differently treated cohorts. In the CHEMO group, after adjustment for multiple testing, none of 
the abnormal BAC clones was associated with tumor relapse (Figure 4A). In the non-CHEMO group, 
however, there were statistically significant differences (p<0,05) in 8 BAC clones that showed more 
common deletion in tumor recurrences with respect to non-recurrences (Figure 4B). Notably, these 8 
clones clustered to the long arm of chromosome 11 from 11q23.1 to 11q24.1, spanning ∼9 Mb. in size 
(Figure 4C). Therefore, deletion of chromosome 11q was associated with decreased DFS in NNBC 
patients in the non-CHEMO group (DFS ± SE at 10 years, 40± 14% vs. 86± 6%, p<0,0001) but not in 
the non-CHEMO group (DFS at 10 years ± SE, 92 ±  21% vs. 65 ± 9%, p=0,13). Analysis of the 
association of the genomic changes with OS in the two treatment cohorts did not reveal any significant 
correlation, probably due to the low number of patients who have died of the disease so far. Finally, we 
performed a statistical analysis to check if there were any GO categories that were enriched in the 
genes located in the region of deletion in chromosome 11q23.1-q24.1. Among them, DNA repair genes 
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and meiotic-related genes were significantly enriched (hypergeometric test pvalue <0.00092). Four 
genes belonged to this category (CHK1, H2A, ATM and ZW10). 
 
CHARACTERISTICS OF PATIENTS WITH 11q DELETIONS 
To determine whether the negative impact of 11q deletion on DFS was dependent on other clinical and 
biological features, we compared the clinical and biological characteristics of the 54 patients with 11q 
deletion vs. those 131 patients without deletion of 11q. In the whole group of 185 patients, there were 
no statistically significant differences for age, clinical stage, hormonal status, tumor size and grade, and 
expression of ER/PR for 11q-deleted vs. non-deleted tumors (Supplemental Table S6). These data 
indicate that the influence of 11q deletions in the relapse rate of the patients in the non-CHEMO group 
is independent of other known clinical and pathological features. We also analyzed possible differences 
in patients with and without 11q deletion for genetic alterations reported in correlation with aggressive 
breast cancer (HER2, CCND1, MYC and FGFR1 amplifications and P53/P16 deletions). We did not 
observe changes in the distribution of these genomic alterations, with the exception of CCND1 
amplification that was more common in tumors harboring deletion of chromosome 11q: among 17 
cases with CCND1 amplification, 12 (70%) presented deletion of 11q whereas only 42 cases (25%) 
showed 11q deletion among the 168 non-amplified CCND1 cases (p<0,001). This association can 
probably be explained by the proximity of CCND1 gene (which maps to 11q13 band) to the 11q23.1-
q24.1 deletion (Supplemental Figure S4B). Notably, genomic amplification of CCND1 was not 
associated with decreased DFS in both the non-CHEMO and CHEMO groups. In summary, tumors 
with 11q deletion do not show a more aggressive phenotype or genotype that can distinguish them 
from those without this chromosome deletion. 
 
VALIDATION OF 11q DELETION AS A THERAPY-PREDICTIVE INDICATOR  
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To validate the association of chromosome 11q deletion with worse outcome in patients not receiving 
anthracycline-based chemotherapy, we analyzed a second series (validation group) of 88 NNBC 
biopsies.  After surgery, 27 of the patients received chemotherapy whereas the remaining did not. 
Sixty-two patients with ER/PR positive expression received hormonal therapy based on tamoxifen. In 
the group treated with chemotherapy, 6 of 15 patients (40%) without 11q deletion relapsed whereas 3 
of 12 patients (25%) with 11q deletion had a recurrence (p=0,23). However, in the group not receiving 
chemotherapy, tumor recurrence was observed in 4 of 33 patients (12%) without 11q deletion and in 10 
of 28 patients (35%) with 11q deletion (p=0,02) (Figure 5). Kaplan-Meier curves also showed that 
deletion of chromosome 11q was associated with inferior DFS in patients not treated with 
chemotherapy (DFS ± SE at 10 years, 65± 13% vs. 88± 8%, p<0,1). Notably, in the non-CHEMO 
group, patients with 11q deletion had a tendency to show a superior DFS compared to those without 
11q loss (73± 18% vs. 50± 18%, p<0,7). These differences, however, did not reach statistically 
significant values, probably because of the limited number of patients and the relatively short median 
follow-up time (Figure 5D). In summary, the results observed in this validation set were coincident with 
the results obtained in the training set of 185 patients, and confirms that deletion of 11q is associated 
with relapse in patients with NNBC who are not treated with anthracycline-based chemotherapy.  
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DISCUSSION 
 
Following current therapeutic guidelines, one fourth of NNBC patients will have tumor recurrence and 
ultimately die of the disease. In addition, many patients treated with systemic therapy who will never 
have disease recurrence could have been cured with surgery alone. These over- and under-treatments 
are owing to limitations of the current prognostic factors, which largely rely on clinical characteristics 
and classical histopathological features.(2-4). Recently, HER2 amplification/over-expression has been 
accepted as a risk factor for prognostication in the St Gallen criteria and moreover, recent reports 
demonstrate that a recombinant monoclonal antibody against HER2 combined with chemotherapy 
improves outcomes among women with HER2-positive breast cancer.(4, 7, 28) Still, as this therapy will 
benefit ∼20% of NNBC women with HER2-positive tumors, there is an urgent need of similar therapy-
predictive factors to tailor optimal individualized therapies in the remaining women. In the present 
study, by using CGH to BAC microarrays for scanning NNBC genomes, we have identified the single 
deletion of chromosome 11q as a novel genomic marker that predicts response to anthracycline-based 
chemotherapy. Thus, patients receiving anthracycline-based chemotherapy with 11q deletion had lower 
tumor relapse rates (although it was not statistically significant) than those not having 11q deletion. On 
the contrary, in the group of patients not receiving chemotherapy, tumors with 11q deletion relapsed 
more frequently than those without 11q loss. Notably, the presence of 11q deletion in tumors was not 
correlated with classical prognostic factors such as age, clinical stage, tumor size, histological grade 
and subtype, and ER and PR expression status, nor with other genetic alterations correlated with poor 
outcome in breast cancer (HER2, MYC and FGFR1 amplification and P53 and P16 deletion).(20, 29) 
There was however a regional association between 11q deletion and amplification of CCND1 gene at 
11q13 band, although genomic amplification of CCND1 did not influence patient outcome. Thus, the 
adverse outcome of 11q deletion in the non-CHEMO group was independent of all tested prognostic 
factors. Therefore, our data suggest that NNBC patients with 11q deleted tumors may benefit from the 
 15 
use of systemic chemotherapy that could be considered as the first treatment option for these patients 
despite other clinical, histopathological and genetic characteristics.  
 
In the attempt of delineating the minimal region of common loss of 11q, we observed that most tumors 
in our study showed large 11q deletions extending from bands 11q21 to 11q25. These data confirm 
previous studies using LOH, standard CGH and array CGH techniques that have reported the loss of 
large areas of 11q as a common event in breast cancer.(17, 19, 30-35) The wide region defined in our 
study overlaps with all these early reports. A number of candidate target tumor suppressor genes 
involved in breast and/or ovarian cancers are mapped to this chromosome region, including the ataxia-
teleangiectasia mutated gene ATM,(36) the gene coding for the CHK1 kinase, which coordinates cell 
cycle progression and preserves genome integrity,(37) the tumor suppressor in lung cancer-1 gene 
TSLC1,(38) and the breast cancer suppressor candidate-1 gene BCSC1.(39) As a consequence of the 
chromosome deletion, we may speculate that any of these genes (or several of them) become altered 
in the tumor cells. Further support to the hypothesis suggesting that 11q may contain gene/s important 
for the suppression of tumorigenesis was provided using microcell-mediated chromosome 11 transfer 
into cancer cells.(40, 41) In addition to the deletion of one allele with loss-of-function mutation of the 
remaining allele as the causative mechanism of inactivation of the putative 11q tumor suppressor 
genes, the 11q loss may also act as haploinsufficient mutation, being the deletion of one chromosome 
enough to perturb gene/s that contribute to cancer progression through a gene-dosage effect.(42) Our 
studies lead us to hypothesize that the large non-random deletions of chromosome 11q are the 
consequence of a yet-unidentified common molecular hit occurring in tumor cells at early stages that 
confers chromosome instability and predisposition to regional 11q loss. Further ongoing genetic and 
functional studies will address these initial questions.  
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The bottom line of our findings is that the loss of chromosome 11q makes tumor cells responsive to 
anthracycline-based chemotherapy. Why 11q-deleted cells become more sensitive to chemotherapy is 
currently unknown. Theoretically, adjuvant systemic chemotherapy is administered to the patients to kill 
any remaining malignant cell (wherever they may be) after surgical removal of the tumor. Cellular DNA 
is the primary target for anthracyclines, by binding and inserting between DNA bases, leading to 
chromatin unfolding and aggregation. These chromatin structural changes primarily interfere with DNA 
replication and transcription, thus leading to the apoptosis undergone by the cells treated with 
anthracyclines.(43) The selectivity of these drugs for targeting cancer cells but not non-tumoral cells 
may reside in the lower ability of cancer cells to repair the damage induced by the drugs.(43) We may 
speculate that deletion of chromosome 11q in breast tumor cells leads to functional impairment of 
gene/s involved in DNA repair, thus contributing to the increased sensitivity to anthracyclines reported 
in our study. Indeed, we have observed that genes involved in DNA repair were enriched in the deleted 
11q region with respect to the rest of the genome. Two of the most prominent candidate targets for 11q 
deletion in breast cancer are 1) the ataxia-teleangiectasia mutated gene ATM that codifies for a protein 
involved in DNA repair and cell cycle control;(44, 45) and 2) the cell cycle checkpoint kinase CHK1, 
that acts downstream of ATM in response to DNA damage.(37) Other candidate targets include the 
gene encoding for the H2AFX histone, which is critical for facilitating the assembly of specific DNA-
repair complexes on damaged DNA;(46) and the gene encoding for the mitotic checkpoint protein 
ZW10.(47) In this theoretical scenario, 11q-deleted tumor cells that become deficient for these DNA 
repair genes cannot detect and/or repair DNA damage induced by anthracyclines whereas tumor cells 
with intact chromosome 11q and functional DNA repair proteins are able of repairing DNA efficiently, 
evade apoptosis, and ultimately metastasize.(48, 49) We may also suggest that deletion of 11q targets 
the non-coding microRNA gene miR125b-1, which is specifically down-regulated in breast cancer and 
may potentially regulate oncogenes such as ETS1, that plays a role in cell growth and has been shown 
over-expressed in breast cancer.(50) 
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Finally, our study could be valuable in the clinical management of patients with NNBC, by adding the 
11q deletion status to the currently accepted prognostic and therapy-predictive markers.(4) According 
to our data, tumors should be screened for the presence or absence of 11q deletion at diagnosis using 
rapid quantitative PCR, FISH and/or mini-array CGH devices using a reduced set of BAC clones. 
These diagnostic tests should allow clinicians to prospectively identify patients who are candidates to 
receive anthracycline-based chemotherapy, such as standard AC/FAC, which are widely used as front-
line therapies in NNBC, irrespective of other clinico-pathological features. In patients presenting factors 
that imply a good prognosis, such as age >35, clinical stage I, low-grade tumors sized >1 cm, and 
ER/PR positivity, systemic chemotherapy could be avoided only if 11q deletion is not identified. 
Although our study requires further validation and refinement, future application of 11q deletion 
measurement as a novel therapeutic indicator in NNBC is clearly challenged. 
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TABLES 
 
Table 1. Clinico-pathological features of 185 patients and tumors with NNBC. Differences 
between patients treated with chemotherapy (CHEMO group) and patients who did not receive 
chemotherapy after surgery (non-CHEMO group).  
 
SUPPLEMENTAL TABLES 
S1. Clinico-pathological characteristics of the 88 NNBC patients and tumors in the validation series. 
S2. Chemotherapeutic schemes of 185 breast cancer patients.  
S3. FISH analysis of frozen tumor samples. Correlation with array CGH results. 
S4. Description of common regions of genomic gain and amplification, hemizygous loss and 
homozygous deletion in lymph node negative breast tumors.  Mb position is based on UCSC Genome 
Browser Human May 2004 version, http://genome.cse.ucsc.edu/ 
S5. Correlation of abnormal BAC clones in ER+ vs. ER- tumors and in PR+ vs. PR- tumors.  
S6. Clinico-pathological and genetic characteristics, and survival rates of patients with 11q deletion vs. 
those without 11q deletion. In CCND1 and HER2 amplification subgroups, no separate statistical 
analysis for CHEMO and non-CHEMO groups could be performed because of the small number of 
patients. NS, non significant.  
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FIGURES 
Figure 1. Representation and description of genome-wide array CGH technique. Genome-wide 
analysis of DNA-copy number changes was performed using array CGH on a microchip with ∼2.460 
BAC and P1 clones printed in triplicate. Briefly, 0.5 µg of test (tumor) and reference genomic DNAs 
were labeled by random priming using Cy3 and Cy5, respectively. After 48 hour of hybridization, slides 
were washed and mounted with DAPI. The images of the arrays were captured using a CCD camera, 
and the “UCSF SPOT” 2.0 software (available at http://www.jainlab.org/downloads.html) was used to 
analyze the images and measure tumoral vs. control fluorescence intensity ratios that were converted 
to the log2 scale. A second program, the “UCSF SPROC” was used to associate clones with each spot 
and to create a mapping information file that allows the data to be plotted relative to the position of the 
BACs on the draft human genome sequence (http://genome.cse.ucsc.edu; May 2004 freeze). A 
formal data filtering procedure was then performed, and a SPROC output file consisting of averaged 
ratios of the triplicate spots for each clone, standard deviations of the replicates and plotting positions 
for each clone on the array, was obtained.  
Figure 2. Representation of array CGH results of 185 NNBC. Genomic gains and losses are 
depicted in green and red, respectively.  
Figure 3. Correlation of ER/PR expression status with genomic data. A. The genomic gain of BAC 
clones mapped to 1q21-q43 and to 16p12 chromosome regions and the genomic loss of clones 
mapped to 16q21-q24 were associated with positive ER (marked with arrowheads). B. The 
progesterone receptor (PR) status is not significantly associated with abnormalities of 1q, 16p or 16q 
arms, but a borderline significance in chromosome 16 is observed. Instead, the genomic loss of clones 
mapped to 4p13-16 and 5q11.2-q31 were observed associated statistically with negative PR (marked 
with arrowheads). C. Frequency plot of all BAC clones in chromosome 16 comparing ER positive (C2) 
versus ER negative (C1) tumors. D. Representation of log2ratios from clones in chromosome 16 in one 
ER-positive breast tumor. 
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Figure 4. Association of genomic results with clinical outcome in NNBC patients. Association of 
genomic results with clinical outcome in NNBC patients. A. In the CHEMO group, after adjustment for 
multiple testing, none of the 2,460 BAC clones was associated with tumor relapse. B. In the non-
CHEMO group, however, there were statistically significant differences (p<0,05) in 8 BAC clones, 
clustered to the long arm of chromosome 11, that showed more common deletion in the group of tumor 
recurrences. Kaplan Meier curves showed differences in disease-free survival (DFS) for 11q deleted 
tumors vs. those without deletion in the non-CHEMO group (DFS ± ES at 10 years, 40± 14% vs. 86± 
6%, p<0,0001) but not in the non-CHEMO group. Considering the patients harboring deletion of 
chromosome 11q, five of 31 patients in the CHEMO group (16%) had recurrence of the disease 
whereas the relapse rate was much higher in the non-CHEMO group: 14 of 23 with 11q deletion (62%) 
had a relapse (p<0,0001). Among the 59 patients in the CHEMO group who did not show deletion of 
11q, 19 (30%) presented recurrence of the disease whereas only 8 of 72 without 11q deletion (11%) in 
the non-CHEMO group relapsed. C. Representation of the region of deletion in chromosome 11q. The 
eight clones clustered to chromosome 11 from bands 11q23.1 to 11q24.1 are highlighted in yellow. 
When the adjusted value for statistical significance was of <0,1 instead of <0,05, the number of BAC 
clones correlated with relapse increased to 24, all of them mapped to 11q21-q25.  
Figure 5. Correlation of 11q deletion in the test and validation series. A. Bars show the 
comparative relapse rates of tumors with 11q vs. non-deleted in 185 NNBC patients (training set). B. 
Relapse rates in the validation set of 88 NNBC patients. C. The distribution of recurrences between the 
11q vs. non-11q subgroups is shown in the training and validation sets. D. Kaplan–Meier curves show 
differences in DFS for the validation group, resembling the data obtained in the training set of 185 
patients. 
 
SUPPLEMENTAL FIGURES. 
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S1. A. Boxplot representing differences between presentation age in both treatment groups (p=0,003). 
Kapplan Meier curves for (B) Disease Free Survival (DFS) and (C) Overall Survival (OS) in CHEMO 
group and non-CHEMO group. 
S2. Comparison of array CGH and CGH to metaphase chromosome techniques in 44 NNBC samples. 
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p-value
Nº % Nº % Nº %
Follow-up (Months) Range NS
Median
Recurrence 45 24% 23 26% 22 23% NS
Age (years) range
47 25% 48 25% 50 25%
mean 58 50% 51 50% 67 50%
70 75% 62 75% 75 75%
0,003
<35 11 6% 9 10% 2 2%
35-50 54 29% 32 36% 22 23%
51-55 16 19% 13 14% 3 3%
>55 104 56% 36 40% 68 72%
Hormonal Status Post- 115 63% 48 53% 67 70% 0,001
Pre- 55 30% 39 43% 16 17%
No data 14 7% 3 4% 11 13%
Tumoral Size
T1 < 2cm 70 39% 27 30% 43 48%
T2 2 - 5cm 100 55% 56 63% 44 48% NS
T3 >5cm 10 6% 6 7% 4 4%
Histologic Type
Ductal Infilt 146 79% 76 85% 70 74% NS
Lobulillar Infilt 13 7% 7 8% 6 6%
Other 26 14% 7 7% 19 20%
Hormonal Receptors ER - 60 32% 33 36% 27 28%
ER+ 101 55% 42 47% 59 62% NS
No data 24 13% 14 16% 9 10%
PgR - 65 35% 32 36% 33 35%
PgR+ 96 52% 43 48% 53 56% NS
No data 24 13% 15 16% 9 9%
Histologic Grade I 41 22% 13 14% 28 30%
II 90 49% 44 49% 46 48% NS
III 17 9% 12 14% 5 5%
No data 37 20% 21 23% 16 17%
Adjuvant Chemotherapy (CHEMO) No Adjuvant Chemotherapy (non-CHEMO)All PatientsClinical Characteristics
N = 90 N = 95N = 185
9 - 218 11 - 1749,2 - 218
85 7782
21 - 73 30 - 8621 - 86
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genomic loss Array Position teststat raw p-value adjusted p-value Clone Name Chromosome band kb_position*
1386 11.41698229 0.0007 0.073 RP11-163O18 11q21 92996.6955
1388 10.21369871 0.0014 0.092 RP11-267L1 11q22.1 97463.707
1401 10.95068946 0.0009 0.076 CTD-2057A4 11q22.2 107741.5585
1402 12.04782451 0.0005 0.072 RP11-2F21 11q22.3 109509.3825
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1404 12.49746445 0.0004 0.072 RP11-262J9 11q23.1 111290.463
1406 23.15356975 <0.00001 0.003 CTD-2059P15C 11q23.1 112785.8575
1407 10.70468829 0.0011 0.078 RP11-5N6 11q23.2 112997.6715
1408 14.04187609 0.0002 0.042 RP11-36M5 11q23.2 113584.738
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1426 11.53493118 0.0007 0.072 RP1-26N8 11q25 134452.384
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